Received radiotherapy to metastatic sites of disease < weeks prior to Day .
Must be  weeks from radiotherapy; if patients are within  weeks of radiotherapy, then the progressive lesion must be outside of the high-dose radiation target volume or have unequivocal evidence of progressive tumor on a biopsy specimen
ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP ): Radiotherapy may be given before or after protocol treatment. when radiotherapy is planned prior to protocol treatment administration, patients must have completed adjuvant radiotherapy >=  weeks prior to randomization for protocol therapy, if applicable
Patients receiving adjuvant radiotherapy within  weeks prior to randomization
Radiotherapy within  weeks of first dose of study drug
Chemotherapy or stereotactic radiotherapy within the last  weeks
Less than four weeks since last radiotherapy (excluding palliative radiotherapy).
Washout time of at least  weeks for prior biological, chemotherapeutic, or radiotherapy
Prior radiotherapy within  weeks of the first dose of study treatment
Radiotherapy:  weeks
PHASE II INCLUSION CRITERIA: For patients who do not receive radiotherapy after chemotherapy, the randomization must occur within  weeks of the last chemotherapy cycle; the study treatment must start within  weeks from randomization; for patients who receive radiotherapy (including prophylactic cranial radiation and/or thoracic radiation) after chemotherapy, the randomization must occur within  weeks of the last chemotherapy cycle but at least  weeks after completion of radiotherapy and the first dose of Lu-DOTA-Tyr-octreotate cannot be given within  weeks of radiotherapy
Has received prior radiotherapy within  weeks of therapy.
Participants who have had radiotherapy within  weeks
Patients who have had radiotherapy within  weeks
Radiotherapy within  weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field
radiotherapy within  weeks prior to treatment with APSF (intensive radiotherapy within  weeks or palliative radiotherapy within  weeks).
Treatment must begin at a minimum of  weeks after, but no later than  weeks after, the date of completion of radiotherapy.
Patient who has received radiotherapy =<  weeks prior to study entry. Palliative radiotherapy for symptomatic control is acceptable (if completed at least  weeks prior to study drug administration and no additional radiotherapy for the same lesion is planned)
Patients must be  weeks beyond previous treatment of any chemotherapy or radiotherapy, and must have recovered to =< grade  or previous baseline for each toxicity. Exception: Patients may have received palliative low dose radiotherapy to the limbs - weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field. Patients who have received non-chemotherapeutic biological agents will need to wait at least  half-lives or  weeks, whichever is shorter, from the last day of treatment of non-chemotherapeutic biological agents.
COHORT : ENDOMETRIAL CANCER: Patients who have undergone radiotherapy within  weeks of first dose of study treatment
Treatment with radiotherapy/radiopharmaceuticals within  weeks before randomization.
Radiotherapy within  weeks of first dose of study medications
Patients may have received prior radiation therapy in either the metastatic or early-stage setting; radiation therapy must be completed per the following timelines:\r\n* Radiotherapy to the thoracic cavity or abdomen within  weeks prior to registration\r\n* Radiotherapy to bone lesions within  weeks prior to registration\r\n* Radiotherapy to any other site within  weeks prior to registration\r\n* NOTE: In all cases, there must be complete recovery and no ongoing complications from prior radiotherapy
Patients who have had radiotherapy within <  weeks are ineligible
Patients who have had radiotherapy within the last  weeks before the first OBP- administration.
Patients who have had chemotherapy or radiotherapy within  weeks of first dose of zydelig
No radiotherapy within  weeks
Treatment must begin at a minimum of  weeks after, but no later than  weeks after, the date of the completion of radiotherapy
Radiotherapy for primary HPVOC within  weeks, or radiotherapy for any other reason within  weeks prior to the first dose of vaccine
Washout of  weeks in case of prior chemotherapy,  weeks if treatment included nitrosoureas;  weeks for definitive radiotherapy, and  weeks for palliative radiotherapy;  months from high-dose chemotherapy and stem cell rescue;  weeks from major surgery. Participants must have recovered from the acute toxic effects of all prior anticancer therapy before enrollment into the study.
Any radiotherapy within  weeks of registration
Radiotherapy less than  weeks before the first dose of study treatment or have not recovered from acute toxic effects from radiotherapy.
Patients must be >=  weeks beyond treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade  toxicity or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs - weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field
Patients must have completed any radiotherapy four weeks prior to study entry, - weeks for local palliative radiotherapy (XRT) (small port)
The patient must have undergone prior external beam radiotherapy to a dose of - Gy to the brain stem; at least  weeks but no more than  weeks must have elapsed from the completion of radiotherapy
Radiotherapy within the  weeks prior to initiation of treatment
Radiotherapy within  weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass
At least  weeks since the last systemic therapy or radiotherapy regimen prior to enrolment
Prior radiotherapy: therapeutic radiotherapy within  weeks, or palliative radiotherapy (to non-CNS disease) within  week
Prior radiotherapy is allowed, provided at least  weeks have elapsed from completion of radiotherapy to initiation of protocol treatment
Major surgery or radiotherapy within  weeks of the first dose of study treatment. Patients who received prior radiotherapy to ? % of bone marrow are not eligible, irrespective of when it was received.
 weeks from radiotherapy
Concurrent radiotherapy or radiotherapy within  weeks prior to randomization or previous radiotherapy at the indicator sites (the sites that are to be followed for determination of a response)
Has received radiotherapy within the  days prior to first dose or within  weeks for patients with glioblastoma, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control.
Radiotherapy or prior systemic chemotherapy within  weeks
Prior radiotherapy (RT) to current field of CNS disease ?  weeks
Radiotherapy within  weeks of protocol therapy
Patients who have had systemic therapy or radiotherapy within  weeks prior to the first dose of study therapy
Patients may have had prior radiotherapy for metastatic disease as long as it was >  weeks prior to registration and the patient has recovered from adverse events associated with the radiotherapy
PHASE II: Patients may have had prior radiotherapy for metastatic disease as long as it was >  weeks prior to randomization and the patient has recovered from adverse events associated with the radiotherapy
At least  weeks after surgery or radiotherapy
Radiotherapy within  weeks prior to study day .
Radiotherapy within  weeks prior to the first dose of lenvatinib.
Concurrent radiotherapy to any site or radiotherapy within  weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)
Have undergone systemic radiotherapy within  weeks prior to study entry, or focal radiotherapy within  weeks prior to study entry.
Radiotherapy to ? % of the bone marrow within  weeks prior to randomization
Radiotherapy within  weeks of the first dose of study drug
Radiotherapy within  weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass
Treatment with radiotherapy within  weeks prior to the first BTCTA (Mosunetuzumab) administration
Prior radiotherapy within  weeks of study treatment
Concurrent radiotherapy to any site or radiotherapy within  weeks prior to enrollment
Concurrent radiotherapy to any site or radiotherapy within  weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)
Radiotherapy <  weeks prior to the first planned dose of study treatment
Participants who have had radiotherapy within  weeks prior to study entry
at least  weeks without tumor progression after any whole brain radiotherapy
PART B: Prior radiotherapy to proposed target lesions is not permitted unless completed more than  weeks prior to treatment within the study and that there has been documented progression at these sites; radiotherapy to non-target lesions is permitted within  weeks of study entry provided all acute effects of the radiotherapy have resolved to =< grade 
Prior full field radiotherapy =<  weeks or limited field radiotherapy =<  weeks prior to enrollment; patients must have recovered from all therapy-related toxicities; the site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease
Radiotherapy within  weeks prior to first dose of FOLFIRI
Radiotherapy within  weeks
Subjects who have received systemic antitumor therapy within  weeks or radiotherapy to target lesions within  weeks before the first dose of study drug, which is longer
Radiotherapy within  weeks before enrollment.
Radiotherapy within  weeks before enrollment.
Any major surgery, radiotherapy or immunotherapy within the  weeks prior to first dose of study drug, or palliative radiotherapy to a single symptomatic lesion within the  weeks prior to first dose of study drugs.
Patients who received radiotherapy within  weeks of entry
Prior radiotherapy within  weeks prior to first dose of study drug
Less than three weeks since the last radiotherapy dose
Participants who have received radiotherapy less than  weeks prior to first dose of study medication
Discontinuation of all other therapies (including other investigational drugs, radiotherapy, or chemotherapy) for the treatment of cancer ? weeks (? weeks if nitrosoureas, ? weeks if radiotherapy) before initiation of study treatment
Subject has had radiotherapy or surgery within the  weeks prior to treatment with ASP.
At least three weeks since the last prior therapy, at least four weeks since completion of any prior radiotherapy
An interval of at least  weeks between prior surgical resection,  weeks from the end of prior radiotherapy
Radiotherapy or systemic therapy within  weeks of baseline
Patients who have received radiotherapy within =<  weeks prior to registration
Any major surgery, radiotherapy, or immunotherapy within the last  weeks. Limited radiotherapy within the last  weeks.
Prior radiotherapy is allowed, provided at least  weeks have elapsed from completion of radiotherapy to initiation of protocol treatment
Radiotherapy less than  weeks before the first dose of study treatment. If prior radiotherapy occurred < to  weeks before study start, as radiated lesions cannot be reliably assessed by fluorodeoxyglucose-positron emission tomography (FDG-PET), nonradiated target lesions are required for eligibility, and prior radiotherapy information must be submitted to the IRC.
Radiotherapy within  weeks or less prior to starting first veledimex dose
Subjects may not have received prior radiotherapy to the index lesion within  weeks
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for bevacizumab) of liver resection
Radiotherapy less than  weeks before the first dose of study treatment.
Radiotherapy to the bone marrow within  weeks prior to enrollment OR within months prior to enrollment if prior radiotherapy to the craniospinal axis or to at least % of the pelvis was received; within  weeks prior to enrollment if local palliative radiotherapy was received.
